Greenwich Stock Today

GLSI -  USA Stock  

USD 8.50  0.55  6.92%

Market Performance
0 of 100
Odds Of Distress
Less than 24
Greenwich Lifesciences is trading at 8.50 as of the 28th of May 2022. This is a 6.92 percent increase since the beginning of the trading day. The stock's open price was 7.95. Greenwich Lifesciences has about a 24 % chance of experiencing some form of financial distress in the next two years of operation but has generated negative returns over the last 90 days. Equity ratings for Greenwich Lifesciences are calculated daily based on our scoring framework. The performance scores are derived for the period starting the 28th of April 2022 and ending today, the 28th of May 2022. Click here to learn more.
Greenwich LifeSciences, Inc., a clinical stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which has completed Phase IIb clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery. The company has 13 M outstanding shares of which 308.41 K shares are currently shorted by private and institutional investors with about 4.64 trading days to cover. More on Greenwich Lifesciences

Greenwich Lifesciences Stock Highlights

Most reasonable investors view market volatility as an opportunity to invest at a favorable price or to sell short against a bearish trend. If you consider yourself one of those investors, make sure you clearly understand your entering position. Greenwich Lifesciences' investment highlights are automatically generated signals that are significant enough to either complement your investing judgment regarding Greenwich Lifesciences or challenge it. These highlights can help you better understand the position you are entering and avoid costly mistakes.
Greenwich Lifesciences generated a negative expected return over the last 90 days
Greenwich Lifesciences has high historical volatility and very poor performance
Net Loss for the year was (5.94 M).
Greenwich Lifesciences currently holds about 19.74 M in cash with (5.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Greenwich Lifesciences has a frail financial position based on the latest SEC disclosures
Roughly 77.0% of the company shares are held by company insiders
Greenwich Lifesciences Fama & French Pharmaceutical Products
Pharmaceutical Products
Fama & French Classification
Greenwich Lifesciences SEC Filings
Greenwich Lifesciences SEC Filings Security & Exchange Commission EDGAR Reports
Average Analyst Recommendation
Analysts covering Greenwich Lifesciences report their recommendations after researching Greenwich Lifesciences' financial statements, talking to executives and customers, or listening in on Greenwich Lifesciences' conference calls. The current trade recommendation is based on an ongoing consensus estimate among financial analysts covering Greenwich Lifesciences. The Greenwich consensus assessment is calculated by taking the average forecast from all of the analysts covering Greenwich Lifesciences.
Strong Buy1 Opinion
Piotroski F Score
Piotroski F-Score is a popular financial indicator that puts together nine criteria to evaluate the financial strength of Greenwich Lifesciences based on its profitability, leverage, liquidity, source of funds, and operating efficiency. It is an academic score (developed by Joseph Piotroski in 2002) to determine the current strength of Greenwich Lifesciences financial position. Scores of 8 and 9 are usually classified as strong value stocks, whereas scores of 2 or below are considered weak value stocks.
 3 - FrailDetails
Current ValueLast YearChange From Last Year 10 Year Trend
Weighted Average Shares10.4 M12.9 M
Significantly Down
Increasing
Slightly volatile
Weighted Average Shares Diluted10.4 M12.9 M
Significantly Down
Increasing
Slightly volatile
Total Assets22.4 M27.2 M
Significantly Down
Increasing
Slightly volatile
Total Liabilities395.3 K385.2 K
Fairly Up
Decreasing
Slightly volatile
Current Assets22.4 M27.2 M
Significantly Down
Increasing
Slightly volatile
Current Liabilities575 K385.2 K
Way Up
Increasing
Very volatile
Total Debt317.1 K247.6 K
Significantly Up
Decreasing
Slightly volatile
Macroaxis Advice
Unlike general analyst consensus, Macroaxis buy hold or sell recommendation is provided in the context of your current investment horizon and risk tolerance. The advice algorithm takes into account all of Greenwich Lifesciences' available fundamental, technical, and predictive indicators. Your current horizon is 90 days - details
Strong SellUndervalued
Financial Strength
Greenwich Lifesciences' financial strength is of vital concern to both outside investors and internal stakeholders. Efficiency and cost control are keys to Greenwich Lifesciences' success, along with its ability to generate sufficient cash flow to pay bills, repay debt, and make a consistent year-to-year profit.
Financial leverage usually refers to the use of borrowed funds to amplify returns from an investment. In general, analyzing the relationship between debt to total assets helps investors to understand Greenwich Lifesciences' financial leverage. It provides some insight into what part of Greenwich Lifesciences' total assets is financed by creditors.
Share Download
Share Download
By using current balance sheet information, investors can analyze the liability, assets, and equity on Greenwich Lifesciences' books and decide whether to invest or hold. Statistics such as return on equity (ROE), debt to equity (D/E) help investors determine how Greenwich Lifesciences deploys its capital and how much of that capital is borrowed.
Liquidity
Greenwich Lifesciences cash flow analysis is essential to understand how it generates and spends money over a specific period. It can also help you figure out where your money is going and how much cash you have available at a given moment. The company currently holds 635.15 K in liabilities. Greenwich Lifesciences has a current ratio of 80.22, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Greenwich Lifesciences until it has trouble settling it off, either with new capital or with free cash flow. So, Greenwich Lifesciences' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Greenwich Lifesciences sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Greenwich to invest in growth at high rates of return. When we think about Greenwich Lifesciences' use of debt, we should always consider it together with cash and equity.

Operating Cash Flow

(4.4 Million)Share
Greenwich Lifesciences (GLSI) is traded on NASDAQ Exchange in USA. It is located in Building 14 and employs 3 people. Greenwich Lifesciences is listed under Pharmaceutical Products category by Fama And French industry classification. The company currently falls under 'Small-Cap' category with current market capitalization of 103.87 M. Market capitalization usually refers to the total value of a company's stock within the entire market. To calculate Greenwich Lifesciences's market, we take the total number of its shares issued and multiply it by Greenwich Lifesciences's current market price. To manage market risk and economic uncertainty, many investors today build portfolios that are diversified across equities with different market capitalizations. However, as a general rule, conservative investors tend to hold large-cap stocks, and these looking for more risk prefer small-cap and mid-cap equities. Greenwich Lifesciences conducts business under Healthcare sector and is part of Biotechnology industry. The entity has 13 M outstanding shares of which 308.41 K shares are currently shorted by private and institutional investors with about 4.64 trading days to cover. Greenwich Lifesciences currently holds about 19.74 M in cash with (5.71 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 1.52.
Check Greenwich Lifesciences Probability Of Bankruptcy
Ownership
The market capitalization of Greenwich Lifesciences is $103.87 Million. Greenwich Lifesciences retains majority of its outstanding shares owned by insiders. An insider is usually defined as a corporate executive, director, member of the board or institutional investor who own at least 10% of the company outstanding shares. 77.35 (percent) of Greenwich Lifesciences outstanding shares that are owned by insiders attests that they have been buying or selling the stock in recent months in anticipation of some upcoming event. Note, that even with negative profits, if the true value of the firm is larger than the current market value, you may still be able to generate positive returns on investment in this company.

Ownership Allocation (%)

Check Greenwich Ownership Details

Greenwich Stock Price Odds Analysis

What are Greenwich Lifesciences' target price odds to finish over the current price? In reference to a normal probability distribution, the odds of Greenwich Lifesciences jumping above the current price in 90 days from now is under 95%. The Greenwich Lifesciences probability density function shows the probability of Greenwich Lifesciences stock to fall within a particular range of prices over 90 days. Given the investment horizon of 90 days Greenwich Lifesciences has a beta of 0.0486. This usually indicates as returns on the market go up, Greenwich Lifesciences average returns are expected to increase less than the benchmark. However, during the bear market, the loss on holding Greenwich Lifesciences will be expected to be much smaller as well. Additionally, the company has a negative alpha, implying that the risk taken by holding this instrument is not justified. Greenwich Lifesciences is significantly underperforming DOW.
  Odds Below 8.5HorizonTargetOdds Above 8.5
5.30%90 days
 8.50 
94.68%
Based on a normal probability distribution, the odds of Greenwich Lifesciences to move above the current price in 90 days from now is under 95 (This Greenwich Lifesciences probability density function shows the probability of Greenwich Stock to fall within a particular range of prices over 90 days) .

Greenwich Stock Institutional Holders

Institutional Holdings refers to the ownership stake in Greenwich Lifesciences that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Greenwich Lifesciences' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Greenwich Lifesciences' value.
InstituionSecurity TypeTotal SharesValue
Vanguard Group IncCommon Shares375.2 K7.4 M
Blackrock IncCommon Shares236.3 K4.6 M
View Greenwich Lifesciences Diagnostics

Greenwich Lifesciences Historical Income Statement

Greenwich Lifesciences Income Statement is one of the three primary financial statements used for reporting Greenwich's overall financial performance over a current year or for a given accounting period. An Income Statement sometimes referred to as the statement of Greenwich Lifesciences revenue and expense. Greenwich Lifesciences Income Statement primarily focuses on the company's revenues and expenses during a particular period.
The current Consolidated Income is estimated to decrease to about (4.9 M). The current Earning Before Interest and Taxes EBIT is estimated to decrease to about (4.9 M) View More Fundamentals

Greenwich Stock Against Markets

Picking the right benchmark for Greenwich Lifesciences stock is fundamental to making educated investment choices. Many naive investors compare their positions with the S&P 500 or with the Nasdaq. But these benchmarks are not all-inclusive and generally should be used only for large-capitalization equities or stock offerings from large companies. When the price of a selected benchmark declines in a down market, there may be an uptick in Greenwich Lifesciences stock price where buyers come in believing the asset is cheap. The opposite is true when the market is bullish; so, accurately picking the benchmark for Greenwich Lifesciences is critical whether you are bullish or bearish towards Greenwich Lifesciences at a given time.

Be your own money manager

Our tools can tell you how much better you can do entering a position in Greenwich Lifesciences without increasing your portfolio risk or giving up expected return. As an individual investor, you need to find a reliable way to track all your investment portfolios. However, your requirements will often be based on how much of the process you decide to do yourself. In addition to allowing all investors analytical transparency into all their portfolios, our tools can evaluate.risk-adjusted returns of your individual positions relative to your overall portfolio.

Did you try this?

Run Options Analysis Now

   

Options Analysis

Analyze and evaluate options and option chains as a potential hedge for your portfolios
All  Next Launch Module

Investing Greenwich Lifesciences

You need to understand the risk of investing before taking a position in Greenwich Lifesciences. The danger of trading Greenwich Lifesciences is mainly related to its market volatility and company specific events. As an investor, you must understand the concept of risk-adjusted return before you start trading. The most common way to measure the risk of Greenwich Lifesciences is by using the Sharpe ratio. The ratio expresses how much excess return you acquire for the extra volatility you endure for holding a more risker asset than Greenwich Lifesciences. The Shape ratio is calculated by using standard deviation and excess return to determine reward per unit of risk. To understand how volatile Greenwich Lifesciences is, you must compare it to a benchmark. Traditionally, the risk-free rate of return is the rate of return on the shortest-dated U.S. Treasury, such as a 3-year bond.
Please check Risk vs Return Analysis. Note that the Greenwich Lifesciences information on this page should be used as a complementary analysis to other Greenwich Lifesciences' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try Insider Screener module to find insiders across different sectors to evaluate their impact on performance.

Complementary Tools for Greenwich Stock analysis

When running Greenwich Lifesciences price analysis, check to measure Greenwich Lifesciences' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenwich Lifesciences is operating at the current time. Most of Greenwich Lifesciences' value examination focuses on studying past and present price action to predict the probability of Greenwich Lifesciences' future price movements. You can analyze the entity against its peers and financial market as a whole to determine factors that move Greenwich Lifesciences' price. Additionally, you may evaluate how the addition of Greenwich Lifesciences to your portfolios can decrease your overall portfolio volatility.
Theme Ratings
Determine theme ratings based on digital equity recommendations. Macroaxis theme ratings are based on combination of fundamental analysis and risk-adjusted market performance
Go
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Go
Price Transformation
Use Price Transformation models to analyze depth of different equity instruments across global markets
Go
My Watchlist Analysis
Analyze my current watchlist and to refresh optimization strategy. Macroaxis watchlist is based on self-learning algorithm to remember stocks you like
Go
Content Syndication
Quickly integrate customizable finance content to your own investment portal
Go
Sync Your Broker
Sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors.
Go
Probability Of Bankruptcy
Get analysis of equity chance of financial distress in the next 2 years
Go
Price Ceiling Movement
Calculate and plot Price Ceiling Movement for different equity instruments
Go
Focused Opportunities
Build portfolios using our predefined set of ideas and optimize them against your investing preferences
Go
Volatility Analysis
Get historical volatility and risk analysis based on latest market data
Go
Is Greenwich Lifesciences' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Greenwich Lifesciences. If investors know Greenwich will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Greenwich Lifesciences listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
The market value of Greenwich Lifesciences is measured differently than its book value, which is the value of Greenwich that is recorded on the company's balance sheet. Investors also form their own opinion of Greenwich Lifesciences' value that differs from its market value or its book value, called intrinsic value, which is Greenwich Lifesciences' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Greenwich Lifesciences' market value can be influenced by many factors that don't directly affect Greenwich Lifesciences' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Greenwich Lifesciences' value and its price as these two are different measures arrived at by different means. Investors typically determine Greenwich Lifesciences value by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Greenwich Lifesciences' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.